Labetuzumab govitecan - Immunomedics
Alternative Names: Anti-carcinoembryonic antigen monoclonal antibody; Anti-CEA monoclonal antibody; anti-CEACAM5-SN-38; GS-0130; hMN-14-SN38; hMN-14-SN38 antibody-drug conjugate; IMMU-0130; IMMU-130; Labetuzumab-SN38 conjugate; SN38-labetuzumab conjugateLatest Information Update: 02 Oct 2021
At a glance
- Originator IBC Pharmaceuticals; Immunomedics
- Developer Immunomedics
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Indolizines; Monoclonal antibodies; Pyrans; Pyrrolidines; Quinolines; Triazoles
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Colorectal cancer
Most Recent Events
- 03 Dec 2020 Immunomedics withdraws enrolment in a phase II trial prior to enrollment for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (NCT01915472)
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 30 Jul 2018 Immunomedics signs a research collaboration agreement with Fred Hutchinson Cancer Research Center for evaluation of labetuzumab govitecan in the treatment of Prostate cancer (Combination therapy)